AbbVie In Hot Seat Over HCV Drugs' Serious Liver Injury Risk
This article was originally published in Scrip
Executive Summary
The US FDA's alert about liver failure and death in patients taking AbbVie Inc.'s hepatitis C fixed-dose combination therapies Viekira Pak and Technivie is a significant setback for a company that already is a distant second in the market behind Gilead Sciences Inc., and the agency's move clears the way for HCV newcomer Merck & Co. Inc.